This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

Abroad (travel likely)RecruitingPHASE2

Conditions

Primary Graft Dysfunction · Lung Transplantation · Acute Lung Injury(ALI) · Natural Killer Cell Mediated Immunity

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of California, San Francisco, San Francisco, California, United States
Contact: Study coordinator (Daniel Calabrese) · Daniel.Calabrese@ucsf.edu · 415-514-8600

Study leads

Daniel Calabrese, MD
Principal Investigator
University of California, San Francisco

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation

Primary Graft Dysfunction · Lung Transplantation

Abroad (travel likely)Recruiting

Philadelphia, United States

Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation

Primary Graft Dysfunction · Lung Transplantation

Abroad (travel likely)Recruiting

Philadelphia, United States

Prospective Reduction Of Transplant Complications Through Enhanced Preservation Therapy to Prevent Primary Graft Dysfunction

Primary Graft Dysfunction

Abroad (travel likely)Recruiting

Toronto, Canada

Exhaled Breath Particles in Lung Transplantation

Lung Transplant Rejection · Primary Graft Dysfunction · Chronic Rejection of Lung Transplant

Abroad (travel likely)Recruiting

Lund, Sweden